Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-06-17 pm EDT			After hours 08:00:00 pm
78.28 ^USD	-3.31%		78.82	+0.69%

Jun. 17	Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	MT
Jun. 17	Trump Administration to Consider Pharma Advertising Crackdown	MT

Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial

Published on 06/10/2025 at 07:32, updated on 06/10/2025 at 11:51

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	Jun. 17	MT
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	Jun. 13
Merck: FDA approves Keytruda for head and neck cancer	Jun. 13	CF
FDA Approves Merck's Anti-PD-1 Therapy	Jun. 13	CI
Merck Receives FDA Approval for Treatment of Head, Neck Cancers	Jun. 13	DJ
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression	Jun. 13	MT
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs	Jun. 12	MT
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs	Jun. 12	RE
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine	Jun. 12	RE
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	Jun. 12	MT
Kennedy's new vaccine adviser was expert witness against Merck vaccine	Jun. 12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	Jun. 12	RE
Merck: Phase 3 trial for dengue vaccine	Jun. 12	CF
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate	Jun. 12	CI
Merck Starts Phase 3 Trial of Dengue Vaccine	Jun. 12	MT
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate	Jun. 12	RE
Drug pricing reform talks with US government lack clarity, industry executives say	Jun. 10	RE
Merck & Co., Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:00 AM	Jun. 10
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	Jun. 10	RE
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	Jun. 10	RE
US FDA approves Merck's RSV antibody for infants	Jun. 10	RE
US FDA approves Merck's RSV antibody for infants	Jun. 09	RE
Merck Gets FDA Approval for Enflonsia to Prevent RSV in Infants	Jun. 09	MT

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Jul. 29 - Q2 2025 Earnings Release

More about the company